| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 9.19 Billion | USD 17.66 Billion | 7.5% | 2024 |
FrequentlyAsked Questions
Dementia and movement disorders are neurological conditions affecting the brain. Dementia causes memory loss, confusion, and cognitive decline, while movement disorders, such as Parkinson’s disease, involve problems with movement control, including tremors, stiffness, or uncoordinated motion.
The global dementia and movement disorders market is expected to grow due to increasing prevalence of neurodegenerative diseases, rising aging population, advancements in diagnostic and therapeutic options, and growing investment in research and development.
According to a study, the global dementia and movement disorders market size was worth around USD 9.19 Billion in 2024 and is expected to reach USD 17.66 Billion by 2034.
The global dementia and movement disorders market is expected to grow at a CAGR of 7.5% during the forecast period.
North America is expected to dominate the dementia and movement disorders market over the forecast period.
Leading players in the global dementia and movement disorders market include Novartis AG, Merck and Co. Inc., Biogen Inc., Bausch Health Companies Inc., Acorda Therapeutics Inc., AbbVie Inc., Johnson and Johnson, GlaxoSmithKline Plc, Eisai Co. Ltd., and Teva Pharmaceutical Industries Ltd, among others.
The report explores crucial aspects of the dementia and movement disorders market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients